At the systemic level, metformin reduces hepatic gluconeogenesis and consequently lowers circulating insulin concentrations, thereby attenuating activation of insulin- and IGF-1-dependent signaling cascades that are frequently co-opted in tumor growth [70]. The gene discussed is IGF1; the disease is neoplasm.